These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7492762)

  • 1. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac.
    Waldmann TA; White JD; Carrasquillo JA; Reynolds JC; Paik CH; Gansow OA; Brechbiel MW; Jaffe ES; Fleisher TA; Goldman CK; Top LE; Bamford R; Zaknoen E; Roessler E; Kasten-Sportes C; England R; Litou H; Johnson JA; Jackson-White T; Manns A; Hanchard B; Junghans RP; Nelson DL
    Blood; 1995 Dec; 86(11):4063-75. PubMed ID: 7492762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of T-cell lymphoma.
    Waldmann TA
    Important Adv Oncol; 1994; ():131-41. PubMed ID: 8206486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation.
    Cooper MM; Robbins RC; Goldman CK; Mirzadeh S; Brechbiel MW; Stone CD; Gansow OA; Clark RE; Waldmann TA
    Transplantation; 1990 Nov; 50(5):760-5. PubMed ID: 2238051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia.
    Waldmann TA; White JD; Goldman CK; Top L; Grant A; Bamford R; Roessler E; Horak ID; Zaknoen S; Kasten-Sportes C
    Blood; 1993 Sep; 82(6):1701-12. PubMed ID: 8400227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1992 Stohlman Memorial Lecture: targeting the IL-2 receptor.
    Waldmann TA
    Leukemia; 1993 Aug; 7 Suppl 2():S151-6. PubMed ID: 8361223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimulating factor.
    Parenteau GL; Dirbas FM; Garmestani K; Brechbiel MW; Bukowski MA; Goldman CK; Clark R; Gansow OA; Waldmann TA
    Transplantation; 1992 Dec; 54(6):963-8. PubMed ID: 1281566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia. The Joseph Goldberger Clinical Investigator Lecture.
    Waldmann TA
    JAMA; 1995 Mar; 273(9):735-7. PubMed ID: 7853633
    [No Abstract]   [Full Text] [Related]  

  • 9. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
    J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
    Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric analysis of expression of interleukin-2 receptor beta chain (p70-75) on various leukemic cells.
    Hoshino S; Oshimi K; Tsudo M; Miyasaka M; Teramura M; Masuda M; Motoji T; Mizoguchi H
    Blood; 1990 Aug; 76(4):767-74. PubMed ID: 2383656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2.
    Waldmann TA; Goldman CK; Bongiovanni KF; Sharrow SO; Davey MP; Cease KB; Greenberg SJ; Longo DL
    Blood; 1988 Nov; 72(5):1805-16. PubMed ID: 2846094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine receptors: a target for immunotherapy of lymphomas.
    Waldmann TA
    Ann Oncol; 1994; 5 Suppl 1():13-7. PubMed ID: 8172810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma.
    Foss FM; Raubitscheck A; Mulshine JL; Fleisher TA; Reynolds JC; Paik CH; Neumann RD; Boland C; Perentesis P; Brown MR; Frincke JM; Lollo CP; Larson SM; Carrasquillo JA
    Clin Cancer Res; 1998 Nov; 4(11):2691-700. PubMed ID: 9829731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
    Chen J; Zhang M; Ju W; Waldmann TA
    Blood; 2009 Feb; 113(6):1287-93. PubMed ID: 18948574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.
    Zhang M; Yao Z; Garmestani K; Axworthy DB; Zhang Z; Mallett RW; Theodore LJ; Goldman CK; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Blood; 2002 Jul; 100(1):208-16. PubMed ID: 12070029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-I-associated disorders.
    Waldmann TA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996; 13 Suppl 1():S179-85. PubMed ID: 8797721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
    J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.